Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2H6NI
|
|||
| Drug Name |
OBI-999
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1/2 | [1] | |
| Company |
OBI Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Globohexaosylceramide (Globo H) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04084366) Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Preclinical Studies of OBI-999: A Novel Globo H-Targeting Antibody-Drug Conjugate. Mol Cancer Ther. 2021 Jun;20(6):1121-1132. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.